Muacevic A, Kreth F W, Mack A, Tonn J-C, Wowra B
Department of Neurosurgery, Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany.
Minim Invasive Neurosurg. 2004 Aug;47(4):203-8. doi: 10.1055/s-2004-818511.
The aim of this study was to analyse treatment effects after stereotactic radiosurgery (SRS) without whole brain radiation therapy (WBRT) as primary treatment for patients harboring brain metastases of renal cell carcinoma (RCC). During an 8-year period, 85 patients with 376 brain metastases from RCC underwent 134 outpatient SRS procedures. 65 % of all patients had multiple brain metastases. The median tumor volume was 1.2 cm (3) (range: 0.1 - 14.2 cm (3)). Mean prescribed tumor dose was 21.2 (+/- 3.2) Gy. Local/distant tumor recurrences were treated by additional SRS in cases of stable systemic disease. Overall median survival was 11.1 months after SRS. The local tumor control rate after SRS was 94 %. Most patients (78 %) died because of systemically progressing cancer. A KPS > 70 and RTOG class I were related to prolonged survival time. Patients of the RTOG groups I, II and III survived for 24.2 months, 9.2 months and 7.5 months, respectively. There was no permanent morbidity after SRS. 11 patients (12.9 %) showed transient radiogenic complications and 3 patients (3.5 %) died because of intratumoral bleedings after SRS. Stereotactic radiosurgery alone achieves excellent local tumor control rates for patients with small brain metastases from renal cell carcinoma.
本研究的目的是分析立体定向放射外科治疗(SRS)后不进行全脑放射治疗(WBRT)作为肾细胞癌(RCC)脑转移患者的主要治疗方法的疗效。在8年期间,85例患有376处RCC脑转移的患者接受了134次门诊SRS治疗。所有患者中有65%有多处脑转移。肿瘤中位体积为1.2 cm³(范围:0.1 - 14.2 cm³)。规定的肿瘤平均剂量为21.2(±3.2)Gy。对于全身疾病稳定的患者,局部/远处肿瘤复发采用额外的SRS治疗。SRS后总体中位生存期为11.1个月。SRS后的局部肿瘤控制率为94%。大多数患者(78%)死于全身进展性癌症。KPS>70和RTOG I级与生存期延长有关。RTOG I、II和III组患者的生存期分别为24.2个月、9.2个月和7.5个月。SRS后无永久性并发症。11例患者(12.9%)出现短暂的放射性并发症,3例患者(3.5%)在SRS后因肿瘤内出血死亡。对于肾细胞癌脑转移的小病灶患者,单纯立体定向放射外科治疗可实现出色的局部肿瘤控制率。